PD-1单抗联合化学药物治疗在局部晚期非小细胞肺癌新辅助治疗中的疗效和安全性分析

doi:10.3969/j.issn.1006-7795.2024.04.012

首都医科大学学报 ›› 2024, Vol. 45 ›› Issue (4): 636-641.doi: 10.3969/j.issn.1006-7795.2024.04.012

• 肺癌新辅助免疫治疗临床研究 • 上一篇下一篇

PD-1单抗联合化学药物治疗在局部晚期非小细胞肺癌新辅助治疗中的疗效和安全性分析

李铁铮, 胥凯凯, 邓钰卿 , 王沛豪, 秦齐, 郭康顺, 王炳仁, 常栋, 崔永^*

首都医科大学附属北京友谊医院胸外科，北京 100050

收稿日期:2024-05-14 出版日期:2024-08-21 发布日期:2024-07-08
通讯作者: 崔永 E-mail:cywork1@sina.com
基金资助:
首都卫生发展科研专项项目（2022-2-2024）。

Analysis of the efficacy and safety of PD-1 inhibitors combined with chemotherapy in neoadjuvant treatment of locally advanced non-small cell lung cancer

Li Tiezheng, Xu Kaikai, Deng Yuqing, Wang Peihao, Qin Qi, Guo Kangshun, Wang Bingren, Chang Dong, Cui Yong^*

Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2024-05-14 Online:2024-08-21 Published:2024-07-08
Supported by:
This study was supported by Capital's Funds for Health Improvement and Research（2022-2-2024）.

摘要/Abstract

摘要： 目的探讨程序性细胞死亡蛋白1（programmed cell death protein 1,PD-1）单抗联合化学药物治疗(以下简称化疗)在局部晚期非小细胞肺癌新辅助治疗中的疗效和安全性。方法回顾性分析2021年6月至2023年6月于首都医科大学附属北京友谊医院胸外科43例接受新辅助免疫治疗联合化疗的局部晚期（ⅡB～ⅢＢ）非小细胞肺癌患者的临床资料，评估其影像学及病理学疗效，并观察免疫相关不良反应。结果影像学疗效评价显示客观缓解率为76.7%，疾病控制率为93.0%。34例（79.1%）接受手术的患者中，R0切除率97.1%、完全病理缓解率为29.4%、主要病理缓解率为55.9%。1～2级免疫相关不良反应发生率为67.4%，3级及以上不良反应发生率为7.0%。结论新辅助PD-1单抗联合化疗治疗非小细胞肺癌疗效显著，病理缓解率及R0切除率高，免疫相关不良反应及手术并发症在可接受范围内，安全性较高。

关键词: PD-1单抗, 免疫治疗, 新辅助治疗, 非小细胞肺癌

Abstract: Objective To investigate the efficacy and safety of programmed cell death protein 1 (PD-1) inhibitors combined with chemotherapy in neoadjuvant treatment for locally advanced non-small cell lung cancer (NSCLC). Methods A retrospective analysis was conducted on clinical data of 43 patients with locally advanced (ⅡB～ⅢB) non-small cell lung cancer who received neoadjuvant immunotherapy combined with chemotherapy in the Department of Thoracic Surgery, Beijing Friendship Hospital from June 2021 to June 2023. The radiological and pathological efficacy were evaluated, meanwhile immune-related adverse events were observed. Results The evaluation of radiological efficacy showed an objective response rate of 76.7% and a disease control rate of 93.0%. Among the 34 patients (79.1%) who underwent surgery, the R0 resection rate was 97.1%, the complete pathological response rate was 29.4%, and the major pathological response rate was 55.9%. The incidence rate of grade 1-2 immune-related adverse events was 67.4%, and the incidence rate of grade 3 or above adverse events was 7.0%. Conclusions Neoadjuvant PD-1 inhibitor combined with chemotherapy for non-small cell lung cancer has significant efficacy, with high rates of pathological response and R0 resection. The immune-related adverse events and surgical complications are within an acceptable range, indicating high safety.

Key words: PD-1 inhibitor, immunotherapy, neoadjuvant therapy, non-small cell lung cancer

中图分类号:

R734.2

李铁铮, 胥凯凯, 邓钰卿, 王沛豪, 秦齐, 郭康顺, 王炳仁, 常栋, 崔永. PD-1单抗联合化学药物治疗在局部晚期非小细胞肺癌新辅助治疗中的疗效和安全性分析[J]. 首都医科大学学报, 2024, 45(4): 636-641.

Li Tiezheng, Xu Kaikai, Deng Yuqing, Wang Peihao, Qin Qi, Guo Kangshun, Wang Bingren, Chang Dong, Cui Yong. Analysis of the efficacy and safety of PD-1 inhibitors combined with chemotherapy in neoadjuvant treatment of locally advanced non-small cell lung cancer[J]. Journal of Capital Medical University, 2024, 45(4): 636-641.

参考文献

［1］ Hyuna S, Jacques F, Rebecca L S, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3): 209-249.
［2］ Lewis J, Gillaspie E A, Osmundson E C, et al. Before or after: evolving neoadjuvant approaches to locally advanced non-small cell lung cancer［J］. Front Oncol, 2018, 8: 5.
［3］ Tomasini P, Greillier L, Boyer A, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small cell lung cancer［J］. J Thorac Dis, 2018, 10(Suppl 9): S1032-S1036.
［4］ Reck M, Rodríguez-Abreu D, Robinson A G, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer［J］. N Engl J Med, 2016, 375(19): 1823-1833.
［5］ Lababede O, Meziane M A. The eighth edition of TNM staging of lung cancer: reference chart and diagrams［J］. Oncologist, 2018, 23(7): 844-848.
［6］中国临床肿瘤学会指南工作委员会. 免疫检查点抑制剂相关的毒性管理指南［M］. 北京：人民卫生出版社，2023: 25-30.
［7］ Saw S P L, Ong B H, Chua K L M, et al. Revisiting neoadjuvant therapy in non-small-cell lung cancer［J］. Lancet Oncol, 2021, 22(11): e501-e516.
［8］ Fournel L, Wu Z R, Stadler N, et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer［J］. Cancer Lett, 2019, 464: 5-14.
［9］ Wang Y, Kim T H, Fouladdel S, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer［J］. Sci Rep, 2019, 9(1): 566.
［10］ Shen K K, Cui J G, Wei Y Q, et al. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: a Meta-analysis［J］. J Thorac Dis, 2018, 10(12): 6636-6652.
［11］ Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial［J］. Lancet Oncol, 2020, 21(11): 1413-1422.
［12］ Provencio M, Serna-Blasco R, Nadal E, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage ⅢA non-small-cell lung cancer (NADIM phase II trial)［J］. J Clin Oncol, 2022, 40(25): 2924-2933.
［13］ Forde P M, Spicer J, Lu S, et al. Abstract CT003: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs. chemo as neoadjuvant treatment (tx) for resectable (ⅠB-ⅢA) non-small cell lung cancer (NSCLC) in the phase 3 checkmate 816 trial［J］. Cancer Res, 2021, 81(13_Suppl): CT003.
［14］ Rhodin K E, Rucker A J, Ready N E, et al. The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons［J］. J Thorac Cardiovasc Surg, 2020, 159(4): 1616-1623.
［15］ Schalper K A, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer［J］. J Natl Cancer Inst, 2015, 107(3): dju435.
［16］ Bott M J, Yang S C, Park B J, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer［J］. J Thorac Cardiovasc Surg, 2019, 158(1): 269-276.
［17］ Shu C A, Gainor J F, Awad M M, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial［J］. Lancet Oncol, 2020, 21(6): 786-795.
［18］ Jia X H, Xu H, Geng L Y, et al. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: a Meta-analysis［J］. Lung Cancer, 2020, 147: 143-153.
［19］倪军, 黄淼, 张力, 等. 非小细胞肺癌围手术期免疫治疗相关不良反应管理的临床诊疗建议［J］. 中国肺癌杂志, 2021, 24(3): 141-160.
［20］ Magee D E, Hird A E, Klaassen Z, et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and Meta-analysis of randomized clinical trials［J］. Ann Oncol, 2020, 31(1): 50-60.

[1]	吴朝真, 郑华, 盛舒言, 张权, 张卉, 李杰, 吕嘉林, 钱哲, 王守正, 李曦, 胡瑛. 新辅助免疫联合化疗在非小细胞肺癌中的初步疗效观察[J]. 首都医科大学学报, 2024, 45(4): 642-648.
[2]	王居巳, 宋伟安, 狄守印, 刘军强, 范博士, 周少华, 岳彩迎, 赵嘉华, 陈思禹, 龚太乾. 新辅助化疗联合免疫抑制剂对Ⅲ期非小细胞肺癌治疗有效性分析[J]. 首都医科大学学报, 2024, 45(4): 660-665.
[3]	郝卓鸿, 云铎, 张颖, 李卉惠, 林海珊, 崔永, 赵磊. 非小细胞肺癌围手术期免疫治疗研究进展———新辅助免疫治疗进展[J]. 首都医科大学学报, 2024, 45(4): 666-677.

PD-1单抗联合化学药物治疗在局部晚期非小细胞肺癌新辅助治疗中的疗效和安全性分析

Analysis of the efficacy and safety of PD-1 inhibitors combined with chemotherapy in neoadjuvant treatment of locally advanced non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价